exposure on this page by purchasing a logo/link, or through sponsorship in general, are requested to contact kongress-ghe @ mh-hannover.de . Transparency According to the guidelines of the German Medical A [...] and safeguard the independence of the medical decision, we disclose the sponsorship as follows: Contact | PCO and CME provider of this conference Verein zur Förderung der Fort- und Weiterbildung in der
this study can be found either online in Journal of Hepatolgoy ( doi: 10.1016/j.jhep.2024.08.014 ). Contact: Prof. Amar Deep Sharma ( sharma.amar @ mh-hannover.de ) and Dr. Asha Balakrishnan ( Balakrishnan
organized regional or class reunions, and implemented fundraising campaigns. For details, please contact the HBRS office (hbrs@mh-hannover.de). You are very welcome to support our activities: Please transfer
summer academy -> For other PhD programs (Epidemiology, Auditory Science, BIOMEDAS etc.) please contact the respective program coordinator! Procedure in short for PhD programs ( might differ from other
and motivation), a CV and transcripts (translated to English or German, if applicable), and the contact addresses of 2 references (if possible) preferably via e-mail and as a single PDF file to: Ponimaskin
über den neuen XBB.1.5 basierten Impfstoff von Biontech veröffentlicht. Im Rahmen der „COVID-19 Contact (CoCo)“-Studie der MHH wurden 53 MHH-Beschäftigte untersucht, die den Impfstoff erhalten haben.
approach We also offer a few places without temporal bone dissection! For more information please contact our colleagues via mail .
looking for talented Postdocs, PhD/MD/Master students. If you are interested in our research, please contact Helenie Kefalakes ( Kefalakes.helenie @ mh-hannover.de ). Weitere Informationen Publikationen Pu
Prof. Dr. Dietmar Manstein Contact: Prof. Dr. Dietmar J. Manstein Medizinische Hochschule Hannover Fritz-Hartmann-Center, OE4350 Carl-Neuberg-Str. 1 D-30625 Hannover Tel: +49-511-532-3700 Fax: +49-511-532-5966
hellzelligem, nicht metastasiertem Nierenzellkarzinom mit sarkomatoiden Anteilen. Prostatakarzinom Contact-02 (XL184-315) Eine randomisierte, offene, kontrollierte Phase-III-Studie zu Cabozantinib (XL184)